Malignant neoplasm of central nervous system

Active Ingredient: Thiotepa

Indication for Thiotepa

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

For this indication, competent medicine agencies globally authorize below treatments:

250-350 mg/m² once a day

Route of admnistration

Intravenous

Defined daily dose

250 - 350 mg per m² of body surface area (BSA)

Dosage regimen

From 250 To 350 mg per m² of body surface area (BSA) once every day

Detailed description

Autologus haematopoietic progenitor cell transplantation

The recommended dose ranges from 250 mg/m²/day (10 mg/kg/day) to 350 mg/m²/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m² (42 mg/kg), during the time of the entire conditioning treatment.

Dosage considerations

Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.

10-14 mg/kg once a day

Route of admnistration

Intravenous

Defined daily dose

10 - 14 mg per kg of body weight

Dosage regimen

From 10 To 14 mg per kg of body weight once every day

Detailed description

Autologus haematopoietic progenitor cell transplantation

The recommended dose ranges from 250 mg/m²/day (10 mg/kg/day) to 350 mg/m²/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m² (42 mg/kg), during the time of the entire conditioning treatment.

Dosage considerations

Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.

Active ingredient

Thiotepa

Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the nitrogen mustard. The radiomimetic action of thiotepa is believed to occur through the release of ethylene imine radicals that, as in the case of irradiation therapy, disrupt the bonds of DNA, e.g. by alkylation of guanine at the N-7, breaking the linkage between the purine base and the sugar and liberating alkylated guanine.

Read more about Thiotepa

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.